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ABSTRACT
Introduction: Therapy of coronavirus disease 2019 (COVID-19) involves evolving algorithms that 
include drugs aimed at reducing disease progression by counteracting two different, but intertwined 
processes: (i) the damage caused by the virus (with antivirals); (ii) the damage caused by a dysregulated 
host response (with immunomodulatory agents).
Areas covered: Herein, we discuss the available evidence on the efficacy and safety of antiviral agents 
employed over the past months for the treatment of COVID-19, and the reasons to be considered for 
antiviral selection.
Expert opinion: The available evidence from randomized controlled trials (RCT) currently discourages 
the use of lopinavir/ritonavir, hydroxychloroquine, and interferons, which did not show improved 
efficacy compared to standard care or placebo. Regarding remdesivir, the current body of evidence 
may conditionally support its use in COVID-19 patients requiring oxygen supplementation but still not 
requiring invasive mechanical ventilation. Finally, neutralizing monoclonal antibodies have been proven 
efficacious in reducing the risk of severe disease development if administered early in the course of the 
disease to patients at risk of progression. The results of the ongoing RCT will certainly be crucial to 
further improve our understanding of the optimal place in therapy of antiviral agents for COVID-19.
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Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, 
is a systemic infectious process, mostly (but not only) present-
ing as a respiratory disease, with severity ranging from mild 
forms to acute hypoxemic respiratory failure needing invasive 
mechanical ventilation [1–3]. Many physiopathological fea-
tures of COVID-19 are still unknown, but some major mechan-
isms have been identified: (i) direct virus-mediated cellular 
cytotoxicity; (ii) dysregulation of the renin–angiotensin–aldos-
terone system; (iii) dysregulated host response; (iv) endothelial 
cell injury with proinflammatory and thrombotic cascades; (v) 
fibrotic tissue reaction [4].
The treatment of COVID-19 currently involves continu-
ously evolving algorithms that were initially based on off- 
label or compassionate administration of drugs aimed at 
reducing disease progression by counteracting two differ-
ent, but intertwined processes: (i) the damage caused by 
the virus (with antiviral agents); (ii) the damage caused by 
the dysregulated host response (with immunomodulatory 
agents) [5–7]. The strategy of aiming at two different targets 
has not changed over the past 12 months, but now results 
from large randomized controlled trials (RCTs) have become 
available to optimize and guide the therapy for COVID-19 
with more solid evidence, although further improvements 
could and will certainly emerge from still ongoing RCTs.
In the present narrative review, we discuss the available 
evidence on the efficacy and safety of antiviral agents 
employed over the past months for the treatment of COVID- 
19, and the reasons to be considered for antiviral selection.
2. Methods
The structure of the present narrative review was finally 
agreed by all authors to be divided into the following main 
sections: (i) lopinavir/ritonavir; (ii) umifenovir and favipiravir; 
(iii) remdesivir; (iv) hydroxychloroquine; (v) neutralizing mono-
clonal antibodies; (vi) other antivirals and agents showing 
antiviral activity in vitro; (vii) conclusion; (viii) expert opinion. 
An inductive PubMed search for each section was conducted 
by different groups of authors, using various combinations of 
pertinent keywords. Eventually, the different drafts were 
merged into a final manuscript that was approved by all 
authors.
3. Lopinavir/ritonavir
Lopinavir/ritonavir (LPV/r) is employed for treating infections 
caused by human immunodeficiency virus 1 (HIV-1). LPV is an 
HIV protease inhibitor administered in association with ritonavir
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(which acts as booster, increasing plasma half-life of LPV). LPV is 
also an inhibitor of the severe acute respiratory syndrome coro-
navirus (SARS-CoV) main protease, a protein crucial for viral repli-
cation which is highly conserved also in SARS-CoV-2 [8,9]. In 2003, 
two retrospective matched cohort studies indicated a possible 
favorable effect of LPV/r in patients with SARS-CoV infection 
[10,11], thus ; thus, it seemed reasonable, at least initially, to 
evaluate its possible use also in patients with SARS-CoV-2 infec-
tion. In this regard, preliminary data in a ferret animal model of 
SARS-CoV-2 infection showed how LPV/r marginally reduced clin-
ical symptoms but did not significantly impact virus titers [12]. 
Nevertheless, due to the widespread availability and lack of alter-
natives, the drug was widely employed in the first phases of 
COVID-19 pandemic.
Initial retrospective reports described a reduced viral 
shedding in patients treated with LPV/r plus interferon-α 
[13], but subsequent larger studies of the same type 
reported opposite results [14]. In a multicentre, prospective, 
open-label, randomized, phase 2 trials conducted in 
Hong Kong, an early triple antiviral therapy with LPV/r 
plus ribavirin plus interferon-β-1b was safe and more effica-
cious than LPV/r alone in alleviating symptoms and short-
ening the duration of viral shedding (7 days vs. 12 days) 
and hospital stay (9 days vs. 14.5 days) in patients with mild 
to moderate COVID-19 [15]. Other doubts about any possi-
ble true LPV/r efficacy were suggested by a randomized, 
controlled, open-label trial involving hospitalized adult 
patients with confirmed SARS-CoV-2 infection conducted in 
China. In this study, treatment with LPV/r was not asso-
ciated, in comparison with standard care, with a difference 
in the time to clinical improvement (hazard ratio [HR] for 
clinical improvement, 1.31; 95% confidence interval [CI], 
0.95 to 1.80) and mortality at 28 days (19.2% vs. 25.0%; 
difference, −5.8%; 95% CI, −17.3 to 5.7). Furthermore, the 
percentages of patients with detectable viral RNA at various 
time points were similar. Overall, no substantial benefits of 
LPV/r treatment were observed compared to standard care 
[16]. Similar results were provided by the RECOVERY trial, 
a large, randomized, controlled, open-label, platform trial, 
performed across 176 hospitals in the United Kingdom. In 
this trial, treatment with LPV/r plus standard care was not 
associated with a reduction in 28-day mortality (23% vs
22%), duration of hospitalization (median of 11 days in 
both groups), and progression to invasive mechanical ven-
tilation (4% in both groups) when compared to standard 
care [17]. Finally, in the large, worldwide, World Health 
Organization (WHO)-sponsored SOLIDARITY trial, the main 
outcome of death occurred in 148 of 1,399 patients receiv-
ing LPV and in 146 of 1,372 receiving its control (rate ratio 
[RR], 1.00; 95% CI, 0.79 to 1.25). No differences in the RR for 
in-hospital deaths were observed even when patients were 
stratified by age (<50 years, 50–69 years, ≥70 years) and 
respiratory support (no mechanical ventilation vs mechan-
ical ventilation) at enrollment. Finally, also the secondary 
outcomes, initiation of ventilation and time to discharge, 
were not reduced in patients treated with LPV/r. The 
WHO’s living guidelines did not report any difference 
between LPV/r and standard care in terms of mortality, 
progression to mechanical ventilation, viral clearance at 
7 days, length of hospitalization, and time to symptoms’ 
resolution, recommending against the use of LPV/r in 
COVID-19 patients [18].
4. Umifenovir and favipiravir
Umifenovir (Arbidol®, ARB), is approved for the prophylaxis and 
treatment of influenza A and B virus infections in China and 
Russia [19]. ARB inhibits virus-mediated fusion with the target 
membrane and blocks virus entry into target cells [20]. Activity 
of ARB against Coronaviridae has been reported in vitro [21,22], 
with a 50% maximal effective concentration and a 50% cytotoxic 
concentration of 4.11 (3.55–4.73) and 31.79 (29.89–33.81) μM, 
respectively, and a clear dose-response curve [23].
The whole number of enrolled patients in studies asses-
sing the use of ARB in patients with SARS-CoV-2 infection is 
quite limited, with conflicting evidence [19]. An RCT evalu-
ated hydroxychloroquine (HCQ) followed by LPV/r in com-
parison to HCQ followed by ARB, with primary outcomes 
hospitalization duration and a composite score of clinical 
improvement at 7 days after admission. The study popula-
tion was quite limited, being composed of two arms of 50 
patients. Overall, the duration of hospitalization in the ARB 
group was shorter than in the LPV/r arm (7.2 versus 
9.6 days) [24].
Favipiravir (FPV) inhibits the RNA-dependent RNA of RNA 
viruses, and is approved for the treatment of influenza in 
China and Japan [25]. In vitro results showed its ability to 
inhibit SARS-CoV-2 in Vero E6 cells, with a half-maximal 
effective concentration of 61.88 μM and a half-cytotoxic 
concentration >400 μM, prompting several in vivo studies 
[26]. In a Russian adaptive, multicenter, open label, rando-
mized, phase 2/3 clinical trial of FPV versus standard care in 
hospitalized patients with moderate COVID-19, patients 
treated with FPV achieved viral clearance (62.5% vs 30% 
at day 5, 92.5% vs 80% at day 10) and apyrexia faster 
(median of 2 days vs 4 days) than those receiving standard 
care only [27]. Conflicting results were provided by other 
small studies, with some [28–30] suggesting a faster 
achievement of clinical cure in patients receiving FPV and 
others not [31]. It should be noted that in some studies FPV 
has been administered in combination with inhaled
Article highlights
● At the very beginning of the COVID-19 pandemic, the use of antiviral 
agents for treating SARS-CoV-2 infection was mostly based on the 
promising results of in vitro studies or limited, previous experiences 
in patients with SARS-CoV infection
● The available evidence from RCT currently discourage the use of 
lopinavir/ritonavir, hydroxychloroquine and interferons, which did 
not show improved efficacy compared to standard care or placebo.
● With regard to remdesivir, the current body of evidence may support 
its use in COVID-19 patients requiring oxygen supplementation but 
still not requiring invasive mechanical ventilation.
● Research efforts in this field should not be discontinued. Indeed, the 
results of ongoing RCT will certainly be crucial to further improve our 
understanding of the optimal place in therapy of antiviral agents for 
COVID-19.
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interferon, therefore results must be interpreted with cau-
tion given potential confounders [28,31].
5. Remdesivir
Remdesivir (RDV or GS-5734) is a prodrug of a nucleotide- 
analog, a wide-spectrum antiviral that has been developed 
against the genus Ebolavirus [32]. It has in vitro activity against 
Coronaviridae such as SARS-CoV-2, and animal studies have 
supported its potential beneficial effects [26,33,34]. The 
mechanism of action of remdesivir ultimately results in the 
inhibition of SARS-CoV-2 RNA-dependent RNA-polymerase, 
which is highly conserved across Coronaviridae, thereby repre-
senting an important target for antiviral development [35].
Wang and colleagues [36] conducted the first double-blind, 
placebo-controlled, randomized trial to investigate the efficacy of 
a 10-day treatment course of RDV in hospitalized patients with an 
oxygen saturation of <94% in room air (or a PaO2/FiO2 of 
<300 mmHg) and pneumonia. In this trial, 158 patients were 
randomized to RDV, and 79 patients to placebo. Time to clinical 
improvement before day 28, the primary outcome, was not met by 
RDV (HR 1.23; 95% CI 0.87 to 1.75) [36]. The 28-day mortality rates 
were 14% (22/158) in the RDV arm and 13% (10/79) in the placebo 
arm (difference of 1.1%; 95% CI −8.1% to 10.3%).
Subsequently, a double-blind, randomized, placebo- 
controlled study was conducted in patients with COVID-19 
(Adaptive COVID-19 Treatment Trial [ACTT-1]) [37]. Five hun-
dred and forty-one patients were randomized to 10 days of 
RDV and 521 to 10 days of placebo. The primary outcome 
measure was time to recovery, and the median period to 
recovery in patients receiving RDV was 10 days vs. 15 days in 
patients receiving placebo (RR 1.29; 95% CI 1.12 to 1.49). 
Participants were also divided into four main subgroups: with-
out supplementary oxygen, with any supplemental oxygen, 
requiring noninvasive ventilation/high-flow oxygen, and 
requiring mechanical ventilation or extracorporeal membrane 
oxygenation. The RR for recovery of these groups were 1.29 
(95% CI 0.91 to 1.83), 1.45 (95% CI 1.18 to 1.79), 1.09 (95% CI 
0.76 to 1.57), and 0.98 (95% CI 0.70 to 1.36), respectively. In the 
intent-to-treat population, the HR for 14-day mortality was 
0.55 (95% CI 0.36 to 0.83) and the HR for 28-day mortality 
was 0.73 (95% CI 0.52 to 1.03). Notably, RDV was associated 
with a reduced 14-day mortality (HR 0.28; 95% CI 0.12 to 0.66) 
and 28-day mortality (HR: 0.30; 95% CI 0.14 to 0.64) in patients 
needing any extra oxygen but not requiring MV. Serious side 
effects were reported in 131 (24.6%) patients who received 
RDV and in 163 (31.6%) patients who received a placebo.
In the SIMPLE-severe trial, an open-label RCT comparing 5- vs. 
10-day courses of RDV, 397 hospitalized patients not receiving 
invasive mechanical ventilation were enrolled [38]. On day 14, 
64% (129/200) and 54% (107/197) of the patients had clinical 
improvement in the 5- and 10-day groups, respectively [36]. 
Adverse events (AEs) were distributed equally in the 5-day and 10- 
day arms, but severe AEs were more frequent in latter [38].
Afterward, Spinner and colleagues randomized patients 
with mild-moderate COVID-19 pneumonia to three arms: 10- 
day RDV, 5-day RDV, or standard treatment, respectively [39]. 
Clinical improvement at day 11 was registered in 70% patients 
in the 5-day RDV arm (135/193), in 65% of patients in the 10-
day RDV arm (126/193) and in 60% of the patients in the 
standard treatment arm (121/200) [39]. Mortality was 0% (0/ 
191) in the 5-day RDV arm, 1% (2/193) in the 10-day RDV arm, 
and 2% (4/200) in the standard treatment arm.
Preliminary data have also been provided by the WHO 
Solidarity trial, a large, global, open-label randomized study 
involving over 11,000 COVID-19 patients in 405 hospitals in 
over 30 countries [40]. RDV was one of the four treatment 
alternatives (with lopinavir/ritonavir, hydroxychloroquine, and 
interferon beta-1a), each compared with standard care, and 
the primary outcome was in-hospital mortality. Secondary 
outcomes were the initiation of ventilation and the duration 
of hospitalization [40]. None of the four treatments showed 
any benefit, although one limitation was a lack of data on the 
duration of symptoms before RDV initiation, and the direction 
of the effect in the subgroup of patients not requiring invasive 
ventilation treated with RDV was toward improved survival 
(see expert opinion below) [40].
6. Hydroxychloroquine
At the beginning of the pandemic, the proposal of HCQ for 
treating COVID-19 patients was based on its possible immu-
nomodulatory effects and in vitro anti-SARS-CoV-2 activity [41]. 
An early small observational retrospective study by Gautret 
et al. suggested (exploratorily) a possible beneficial effect in 
reduction of SARS-CoV-2 viral load in specimens from the 
respiratory tract [42]. However, other subsequent exploratory 
studies yielded contradictory findings, more often suggesting 
no beneficial effect on different endpoints [43–45].
In an open-label RCT, 194 participants were randomized to 
HCQ (400 mg twice daily on the first day, then 200 mg twice 
daily for a total of 15 days) or standard treatment alone. All 
patients were hospitalized but not mechanically ventilated at 
enrollment [46]. With regard to primary endpoints, recovery 
within 28 days was registered in 54% of the patients in the 
HCQ arm (52/97) and in 34% of the patients in the standard 
care arm (33/97) [46]. Overall, 4.1% (4/97) of the HCQ patients 
and 5.2% (5/97) of the standard group patients required inva-
sive mechanical ventilation by 28 days, and 28-day mortality 
was 6% (6/97) in HCQ-treated patients and 5% (5/97) in 
patients receiving standard care alone.
Another open-label RCT randomly allocated hospitalized 
COVID-19 patients with mild-to-moderate disease into three arms: 
standard care, HCQ (400 mg twice daily for 7 days) plus standard 
care or HCQ (400 mg twice daily for 7 days) plus azithromycin 
(500 mg once daily) plus standard care [47]. With respect to the 
primary efficacy endpoint, i.e., clinical status at day 15, no advan-
tage was observed for HCQ or azithromycin plus HCQ vs. standard 
care (OR 1.21, 95% CI 0 to 2.12, and OR 0.99, 95% CI 0 to 1.73, 
respectively). Overall, 7.5% of HCQ patients (12/159) and 11.0% of 
HCQ plus azithromycin patients required invasive mechanical ven-
tilation vs. 6.9% (12/173) of those receiving standard care (OR 1.15 
for HCQ, 95% CI 0.49 to 2.70, and OR 1.77 for HCQ plus azithromy-
cin, 95% CI 0.81 to 3.87). In-hospital mortality was 4.4% (7/159), 
2.9% (5/172), and 3.5% (6/173) in patients in the HCQ, HCQ plus 
azithromycin, and standard care arms, respectively.
In the RECOVERY RCT, different treatments were evaluated for 
patients hospitalized with COVID-19, using 28-day mortality as
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the primary efficacy endpoint [48]. The 28-day mortality was 27% 
in the HCQ arm (421/1561) and 25% (790/3155) in the standard 
care arm (RR 1.09, 95% CI 0.97 to 1.23). In patients without 
mechanical ventilation at enrollment, an increased risk of disease 
progression (composite of mechanical ventilation or death) was 
registered in the HCQ arm (RR 1.14, 95% CI 1.03 to 1.27).
In the WHO Solidarity trial, HCQ was one of the four treatment 
alternatives (with lopinavir/ritonavir, RDV and interferon beta-1a) 
[40]. There was no benefit in the primary and secondary outcomes 
in the HCQ arm as compared to the standard treatment group. 
Finally, no effect of HCQ on short-term mortality in hospitalized 
COVID-19 patients was highlighted in two meta-analyses [49,50]. 
Three RCTs investigated changes in viral load as primary endpoints, 
also showing no substantial advantages [51–53].
7. Neutralizing monoclonal antibodies
Neutralizing monoclonal antibodies (mAbs) bind to the virus with 
high affinity and interfere with cell entry, as their target is the 
receptor-binding domain of the spike protein of SARS-CoV-2 
(through which the virus interacts with the cell-surface angiotensin- 
converting enzyme 2 receptors, starting the entry process) [54]. 
Two combinations are currently available for emergency use in 
the US and Europe: (i) bamlanivimab plus etesevimab; (ii) casirivi-
mab plus imdevimab. Bamlanivimab was previously available also 
as monotherapy, but the authorization for emergency use has 
recently been withdrawn in the USA due to an increased risk of 
impaired activity in patients harboring some SARS- 
CoV-2 variants (e.g., those including the E484K mutation) [55].
Neutralizing mAbs are administered to reduce the risk of pro-
gression to severe disease, following favorable evidence from RCTs. 
In a double-blind RCT conducted in 531 outpatients with mild to 
moderate COVID-19, 2800 mg of bamlanivimab plus 2800 mg were 
associated with improved decrease of viral load compared to 
placebo at day 11 (log viral load difference −0.57; 95% CI −1.00 to 
−0.14). Of note, 0% vs. 13.5% hospitalizations were observed in the 
subgroup of patients ≥65-year-old receiving bamlanivimab plus 
etesevimab vs. placebo, respectively [56]. In another double-blind 
RCT (interim analysis), casirivimab plus imdevimab were compared 
to placebo in 275 non-severe COVID-19 outpatients with onset of 
symptoms <7 days [57]. The least-squares mean difference 
between mAbs and placebo arms in the time-weighted viral load 
average change was −0.41 log10 cp per mL (95% CI −0.71 to −0.10), 
with the effect being more marked in serum-negative patients at 
baseline (−0.56 log10 cp per mL, with 95% CI from −1.02 to −0.11). 
Medical visits were necessary in 3% vs. 6% of the patients in 
casirivimab plus imdevimab vs. placebo arms, respectively [57].
8. Other antivirals and agents showing antiviral 
activity in vitro
Interferons have been proposed for the treatment of patients 
with COVID-19 based on their possible immunomodulatory 
effects and in vitro anti-SARS-CoV-2 activity [58]. In the WHO 
Solidarity trial, interferon beta-1a was administered subcuta-
neously in three doses of 44 μg over 6 days. The in-hospital 
mortality was 11.9% (243/2050) in the interferon beta-1a arm 
vs. 11.0% (216/2050) in the standard care arm, with a RR of 
1.16 (95% CI 0.96 to 1.39) [40]. In the subgroup of patients
not receiving mechanical ventilation at enrollment, progres-
sion to mechanical ventilation or death was similar in the 
two arms, with a RR of 0.99 (95% CI 0.80 to 1.24) [40]. On 
October 16, 2020, randomization to interferon beta-1a was 
ceased for futility [40]. On the other hand, some encouraging 
results were provided in a phase 2, double-blind RCT com-
paring nebulized interferon beta-1a (48 patients) vs. placebo 
(51 patients) for the treatment of hospitalized patients with 
COVID-19 [59]. The primary endpoint was a change in clinical 
conditions on the WHO Ordinal Scale for Clinical 
Improvement (OSCI) scale, with patients on the interferon 
beta-1a showing better improvement on the OSCI scale 
on day 15–16 than patients receiving placebo (odds ratio 
2.32, with 95% CI from 1.07 to 5.04). No substantial differ-
ences were observed between arms in terms of tolerability, 
and deaths occurred in 0 and 3 patients in the interferon and 
placebo arms, respectively [59]. Larger RCTs remain neces-
sary to confirm these preliminary positive findings.
The combination of favipiravir plus inhaled interferon beta- 
1b vs HCQ was evaluated in a RCT on 89 COVID-19 patients 
with moderate-to-severe COVID-19, showing no differences 
between the two groups regarding admission to the ICU, 
time to recovery, and mortality [31].
Daclatasvir (DCV) and sofosbuvir (SOF) are drugs used for 
treating hepatitis C, which have also been evaluated against 
SARS-CoV-2, with some promising effects in in silico and 
in vitro studies [60,61]. Two small (44 and 68 patients with 
moderate/severe SARS-CoV-2 infection), open-label RCT were 
conducted in Iran [62,63]: in one study adding SOF/DCV to 
standard care was associated with reduced length of hospital 
stay vs. standard care [62]; in the other one, mortality and ICU 
admissions were similar in the two arms (sofosbuvir/daclatas-
vir vs. standard care) [63].
Leflunomide, a pyrimidine synthesis inhibitor, was also evalu-
ated in a single-center RCT [64]. Its use in patients with prolonged 
viral shedding showed no benefit in terms of the duration of viral 
shedding of the combination leflunomide/interferon alfa-2a vs. 
interferon alfa-2a alone [64].
Novaferon, a recombinant interferon-like protein, was evaluated 
alone or in combination with LPV/r, in patients with moderate to 
severe COVID-19: data reported a 3-day reduction in time to nega-
tive conversion of SARS-CoV-2 molecular tests for patients treated 
with novaferon alone or in combination with LPV/r compared to 
the LPV/r monotherapy, a preliminary finding deserving further 
investigation [65].
Finally, the antibiotic azithromycin has been reported to inter-
fere with virus entry into cells [66]. The largest RCT currently avail-
able (1323 patients) is an open-label study conducted on 
outpatients with suspected COVID-19, with azithromycin resulting 
not associated with improved recovery compared with standard 
care alone (HR 1.08; 95% Bayesian credibility interval 0.95–1.23). 
Similar results were observed in the subgroup of patients with 
confirmed SARS-CoV-2 infection [67].
9. Conclusion
Based on moderate to high certainty of evidence stemming 
from RCT conducted in patients with COVID-19 that have
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become available in the past few months, no substantial 
beneficial effects of lopinavir/ritonavir and hydroxychloro-
quine can be identified, whereas a limited, but favorable effect 
of remdesivir has been described in patients requiring oxygen 
supplementation still not subjected to invasive mechanical 
ventilation. Regarding ARB and FVP, large RCTs remain neces-
sary to clearly delineate any possible place in therapy for these 
two antivirals.
While the available evidence may already be sufficient to 
support the development of dedicated guidelines, research 
efforts in this field should not be discontinued. Indeed, the 
results of ongoing RCT will certainly be crucial to further 
improve our understanding of the optimal place in therapy 
of antiviral agents for COVID-19.
10. Expert opinion
Selection of antiviral agents for the treatment of patients with 
COVID-19 has been an evolving process over the past 12 months. 
At the very beginning of the COVID-19 pandemic, the use of 
antiviral agents for treating SARS-CoV-2 infection was mostly 
based on the promising results of in vitro studies or limited, pre-
vious experiences in patients with SARS-CoV infection. This off-label 
and compassionate use was nonetheless much debated. On the 
one hand, the principle of “first, do not harm” certainly held true [7], 
discouraging the use of drugs outside approved indications with-
out clinical studies providing sufficient evidence in terms of efficacy 
or effectiveness. On the other hand, at the beginning there were 
obviously neither clinical studies nor alternative agents for treating 
COVID-19 patients. From this perspective, in our opinion it was 
reasonable to consider the use of potentially effective agents 
(based on preliminary in vitro or in vivo data) in those patients 
worsening despite adequate supportive care, also as off-label/com-
passionate use whenever the patients could not be enrolled in RCTs 
(that remained the priority, in order to ultimately provide high 
certainty of evidence to optimize treatment algorithms and 
improve patients’ care) [6].
Over the subsequent months, this scenario has, fortunately, 
rapidly changed, with the release of results from RCTs. The 
available evidence from RCTs, described in the previous sec-
tions, currently discourage the use of lopinavir/ritonavir, 
hydroxychloroquine and interferons, which did not show 
improved efficacy compared to standard care or placebo. 
With regard to remdesivir, the scenario is more complex. 
Indeed, while preliminary evidence from the open-label 
Solidarity RCT does not fully support use of remdesivir even 
in the subgroup of patients needing oxygen supplementation 
but not invasive ventilation (i.e., in those patients in whom the 
drug was efficacious in the ACTT-1 RCT), it is of note that the 
direction of the effect was toward reduced mortality (RR 0.86, 
with 95% CI 0.67–1.11), which is in line with the reduced 
mortality observed in the ACTT-1 RCT in the similar subgroup 
of patients who were not under invasive mechanical ventila-
tion at baseline (HR for 28-day fatality 0.30, with 95% CI 0.-
14–0.64) [37,40]. In our opinion, pending complete results of 
the Solidarity RCT, the current body of evidence may support 
the use of remdesivir in patients requiring oxygen supplemen-
tation but still not requiring invasive mechanical ventilation,
although it should be acknowledged that the true magnitude 
of this favorable effect still remains controversial.
Eventually, we think three important points should be 
stressed. The first is that, after only 1 year of COVID-19, we 
are discussing the use of antivirals on the basis of RCT and not 
only observational studies. This is extremely important to 
optimize therapeutic algorithms, and has also shown us once 
again that, for anti-infective agents, observational studies may 
be strongly affected by residual and unmeasured confound-
ing, and possibly by publication bias, and should only be 
considered as hypothesis-generating (i.e., to be confirmed/ 
refuted by RCT, as correctly was the case for antivirals dis-
cussed in the present review). The second point is that, in 
addition to antivirals, immunomodulatory agents have also 
been (and still are) tested in RCT for the treatment of COVID- 
19, with well-known positive results for steroid administration 
in severely ill patients. From this standpoint, we think an 
intriguing field of research for the future is the combined 
use of antiviral and immunomodulatory agents, in the context 
of a balanced approach taking into account the possible 
different timing of administration and the different patients’ 
phenotypes (based on laboratory or genetic data), which it is 
plausible may also explain why no antiviral treatment (if eval-
uated alone independent of immunomodulatory agents) has 
been proven very efficacious up to now, although this con-
sideration still remains largely speculative pending further 
dedicated investigation. Finally, neutralizing monoclonal anti-
bodies also interferes with viral activity (e.g., by preventing 
membrane fusion or by prompting antibody-dependent cell 
cytotoxicity [68]), and may be an important weapon against 
SARS-CoV-2 in the early phases of the disease. A proposal of 
treatment algorithm in patients with COVID-19, including the 
current role of antivirals pending further RCT results, is shown 
in Figure 1.
Overall, we truly welcome this new complex scenario, in 
which classical antiviral agents, neutralizing monoclonal anti-
bodies, and anti-inflammatory or immunomodulatory agents 
are carving out their place in therapeutic algorithms based on 
RCT results (i.e., on high-level evidence) [69]. We should con-
tinue on this path.
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